Global Cord Blood EBIT

Global Cord Blood (CO) currently reports a EBIT of $590M as of July 2022. That compares with $570M in the prior-year period — up 4.7% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Global Cord Blood's EBIT history and peer comparisons.

Global Cord Blood's EBIT increased from $570M to $590M — a 4.7% year-over-year increase (period ending July 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Global Cord Blood's EBIT of $590M is lower than the Healthcare sector average of $22B. That is roughly 97.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Global Cord Blood reported $590M in EBIT as of July 2022. That compares with $570M in the prior-year period — up 4.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $590M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Global Cord Blood, and consider following CO for alerts when major investors trade the stock.